Navigation Links
Squamous Cell Cancer Responds to SPDT Therapy
Date:1/5/2012

SARASOTA, Fla., Jan. 5, 2012 /PRNewswire/ -- George Miller developed an ulcer on his bottom lip that began to bleed.  His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC).  According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals. 

Squamous cell cancers can occur on the skin, lips, mouth, esophagus, bladder, prostate, lung,  vagina and cervix.  In 2010, there were more than 1 million new cases in the United States.  Most are removed surgically, and the site is treated with external beam radiation or internal radiation (brachytherapy).  Treatment is based on the size, type, location and depth of penetration, plus age and health condition of the patient.  Physicians often use Mohs surgery to slice off the tumor, then remove a very thin layer around the lesion to check for malignant cells.  If cancer cells are found, they slice off another layer and check again, until they reach a slice with no cancer cells.  This surgery is most commonly done on the face and hands.  Still, SCC tends to recur within 2 years at the same site, even with clean margins.

Risk factors include smoking, alcohol use and hematopoietic stem cell transplants.  Over exposure to UV rays and exposure to arsenic in water in industrial areas also raise the risk of SCC.

About 30% of mouth and throat cancers develop from the Human Papillomavirus (HPV).  Symptoms include reddish areas or lesions, often with intermittent bleeding, or ulcers with hard raised edges. 

Other lip and oral cavity cancers may present as a white or red patch or lump on the gum, tongue, tonsils or lining of the mouth, loose teeth, swelling of the jaw, sore throat, trouble swallowing and change of voice.  These cancers are often detected during a routine dental exam.  While thes
'/>"/>

SOURCE TMD Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
8. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... CARLOS, Calif., Jan. 5 Nektar Therapeutics,(Nasdaq: ... Robin, is,scheduled to present at the upcoming 27th Annual ... St. Francis Hotel on Tuesday,January 13, 2009 at 10:00 ... The presentation will be accessible via ...
... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
Cached Biology Technology:Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... JUPITER, FL, October 26, 2010 The Scripps Research Institute ... Fox Foundation to study a pair of genetic mutations that ... for Parkinson,s disease, a progressive and fatal neurodegenerative disorder. ... director for drug discovery at Scripps Florida, is the principal ...
... the brain, which scavenge pathogens and damaged neurons, are also ... by Duke neuroscientists. Earlier studies by Staci Bilbo, an ... rats experiencing an infection at an early age have an ... learning and memory. In a study published in ...
... has a companion among emerging futuristic "e-sensing" devices intended ... is a "magnetic tongue" -- a method used to ... sweet, bitter, sour, etc. A report on use of ... Journal of Agricultural and Food Chemistry . ...
Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3